TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. PY - 2011 DA - 2011// TI - Improved survival with vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Robert, C. AU - Thomas, L. AU - Bondarenko, I. PY - 2011 DA - 2011// TI - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1104621 DO - 10.1056/NEJMoa1104621 ID - Robert2011 ER - TY - JOUR AU - Falchook, G. S. AU - Lewis, K. D. AU - Infante, J. R. PY - 2012 DA - 2012// TI - Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70269-3 DO - 10.1016/S1470-2045(12)70269-3 ID - Falchook2012 ER - TY - JOUR AU - Flaherty, K. T. AU - Infante, J. R. AU - Daud, A. PY - 2012 DA - 2012// TI - Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1210093 DO - 10.1056/NEJMoa1210093 ID - Flaherty2012 ER - TY - JOUR AU - Flaherty, K. T. AU - Robert, C. AU - Hersey, P. PY - 2012 DA - 2012// TI - Improved survival with MEK inhibition in BRAF-mutated melanoma JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1203421 DO - 10.1056/NEJMoa1203421 ID - Flaherty2012 ER - TY - JOUR AU - Hauschild, A. AU - Grob, J. J. AU - Demidov, L. V. PY - 2012 DA - 2012// TI - Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60868-X DO - 10.1016/S0140-6736(12)60868-X ID - Hauschild2012 ER - TY - JOUR AU - Kim, K. B. AU - Kefford, R. AU - Pavlick, A. C. PY - 2013 DA - 2013// TI - Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.5966 DO - 10.1200/JCO.2012.43.5966 ID - Kim2013 ER - TY - JOUR AU - Hamid, O. AU - Robert, C. AU - Daud, A. PY - 2013 DA - 2013// TI - Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305133 DO - 10.1056/NEJMoa1305133 ID - Hamid2013 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Wolchok, J. D. PY - 2014 DA - 2014// TI - Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60958-2 DO - 10.1016/S0140-6736(14)60958-2 ID - Robert2014 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Weber, J. S. AU - D’Angelo, S. P. AU - Minor, D. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Chambers, C. A. AU - Kuhns, M. S. AU - Egen, J. G. AU - Allison, J. P. PY - 2001 DA - 2001// TI - CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy JO - Annu Rev Immunol VL - 19 UR - https://doi.org/10.1146/annurev.immunol.19.1.565 DO - 10.1146/annurev.immunol.19.1.565 ID - Chambers2001 ER - TY - JOUR AU - Bosch, X. AU - Saiz, A. AU - Ramos-Casals, M. AU - Group, B. S. PY - 2011 DA - 2011// TI - Monoclonal antibody therapy-associated neurological disorders JO - Nat Rev Neurol VL - 7 UR - https://doi.org/10.1038/nrneurol.2011.1 DO - 10.1038/nrneurol.2011.1 ID - Bosch2011 ER - TY - JOUR AU - Min, L. AU - Vaidya, A. AU - Becker, C. PY - 2011 DA - 2011// TI - Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy JO - Eur J Endocrinol VL - 164 UR - https://doi.org/10.1530/EJE-10-0833 DO - 10.1530/EJE-10-0833 ID - Min2011 ER - TY - JOUR AU - Akhtari, M. AU - Waller, E. K. AU - Jaye, D. L. PY - 2009 DA - 2009// TI - Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody) JO - J Immunother VL - 32 UR - https://doi.org/10.1097/CJI.0b013e31819aa40b DO - 10.1097/CJI.0b013e31819aa40b ID - Akhtari2009 ER - TY - JOUR AU - Johnston, R. L. AU - Lutzky, J. AU - Chodhry, A. AU - Barkin, J. S. PY - 2009 DA - 2009// TI - Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab JO - Dig Dis Sci VL - 54 UR - https://doi.org/10.1007/s10620-008-0641-z DO - 10.1007/s10620-008-0641-z ID - Johnston2009 ER - TY - JOUR AU - Minor, D. R. AU - Chin, K. AU - Kashani-Sabet, M. PY - 2009 DA - 2009// TI - Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis JO - Cancer Biother Radiopharm VL - 24 UR - https://doi.org/10.1089/cbr.2008.0607 DO - 10.1089/cbr.2008.0607 ID - Minor2009 ER - TY - JOUR AU - Blansfield, J. A. AU - Beck, K. E. AU - Tran, K. PY - 2005 DA - 2005// TI - Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer JO - J Immunother VL - 28 UR - https://doi.org/10.1097/01.cji.0000178913.41256.06 DO - 10.1097/01.cji.0000178913.41256.06 ID - Blansfield2005 ER - TY - JOUR AU - Dillard, T. AU - Yedinak, C. G. AU - Alumkal, J. AU - Fleseriu, M. PY - 2010 DA - 2010// TI - Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes JO - Pituitary VL - 13 UR - https://doi.org/10.1007/s11102-009-0193-z DO - 10.1007/s11102-009-0193-z ID - Dillard2010 ER - TY - JOUR AU - Graziani, G. AU - Tentori, L. AU - Navarra, P. PY - 2012 DA - 2012// TI - Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer JO - Pharmacol Res VL - 65 UR - https://doi.org/10.1016/j.phrs.2011.09.002 DO - 10.1016/j.phrs.2011.09.002 ID - Graziani2012 ER - TY - JOUR AU - Prieto, P. A. AU - Yang, J. C. AU - Sherry, R. M. PY - 2012 DA - 2012// TI - CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-1823 DO - 10.1158/1078-0432.CCR-11-1823 ID - Prieto2012 ER - TY - JOUR AU - Weber, J. PY - 2009 DA - 2009// TI - Ipilimumab: controversies in its development, utility and autoimmune adverse events JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0653-8 DO - 10.1007/s00262-008-0653-8 ID - Weber2009 ER - TY - JOUR AU - Wolchok, J. D. AU - Neyns, B. AU - Linette, G. PY - 2010 DA - 2010// TI - Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(09)70334-1 DO - 10.1016/S1470-2045(09)70334-1 ID - Wolchok2010 ER - TY - JOUR AU - Beck, K. E. AU - Blansfield, J. A. AU - Tran, K. Q. PY - 2006 DA - 2006// TI - Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.5716 DO - 10.1200/JCO.2005.04.5716 ID - Beck2006 ER - TY - JOUR AU - Maker, A. V. AU - Phan, G. Q. AU - Attia, P. PY - 2005 DA - 2005// TI - Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study JO - Ann Surg Oncol VL - 12 UR - https://doi.org/10.1245/ASO.2005.03.536 DO - 10.1245/ASO.2005.03.536 ID - Maker2005 ER - TY - JOUR AU - Robinson, M. R. AU - Chan, C. C. AU - Yang, J. C. PY - 2004 DA - 2004// TI - Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis JO - J Immunother VL - 27 UR - https://doi.org/10.1097/00002371-200411000-00008 DO - 10.1097/00002371-200411000-00008 ID - Robinson2004 ER - TY - JOUR AU - Kaehler, K. C. AU - Piel, S. AU - Livingstone, E. PY - 2010 DA - 2010// TI - Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management JO - Semin Oncol VL - 37 UR - https://doi.org/10.1053/j.seminoncol.2010.09.003 DO - 10.1053/j.seminoncol.2010.09.003 ID - Kaehler2010 ER - TY - JOUR AU - Lecouflet, M. AU - Verschoore, M. AU - Giard, C. PY - 2013 DA - 2013// TI - Orbital myositis associated with ipilimumab JO - Ann Dermatol Venereol VL - 140 UR - https://doi.org/10.1016/j.annder.2013.02.029 DO - 10.1016/j.annder.2013.02.029 ID - Lecouflet2013 ER - TY - JOUR AU - McElnea, E. AU - Ni Mhealoid, A. AU - Moran, S. PY - 2014 DA - 2014// TI - Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab JO - Orbit VL - 33 UR - https://doi.org/10.3109/01676830.2014.949792 DO - 10.3109/01676830.2014.949792 ID - McElnea2014 ER - TY - JOUR AU - Papavasileiou, E. AU - Prasad, S. AU - Freitag, S. K. PY - 2016 DA - 2016// TI - Ipilimumab-induced ocular and orbital inflammation-a case series and review of the literature JO - Ocul Immunol Inflamm VL - 24 ID - Papavasileiou2016 ER - TY - STD TI - Sheldon CA, Kharlip J, Tamhankar MA. Inflammatory Orbitopathy Associated with Ipilimumab. Ophthal Plast Reconstr Surg 2015. PMID:26068559. [Epub ahead of print]. ID - ref33 ER - TY - JOUR AU - Audemard, A. AU - Raucourt, S. AU - Miocque, S. PY - 2013 DA - 2013// TI - Melanoma-associated retinopathy treated with ipilimumab therapy JO - Dermatology VL - 227 UR - https://doi.org/10.1159/000353408 DO - 10.1159/000353408 ID - Audemard2013 ER - TY - JOUR AU - Crosson, J. N. AU - Laird, P. W. AU - Debiec, M. PY - 2015 DA - 2015// TI - Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma JO - J Immunother VL - 38 UR - https://doi.org/10.1097/CJI.0000000000000066 DO - 10.1097/CJI.0000000000000066 ID - Crosson2015 ER - TY - JOUR AU - Mantopoulos, D. AU - Kendra, K. L. AU - Letson, A. D. AU - Cebulla, C. M. PY - 2015 DA - 2015// TI - Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma JO - JAMA Ophthalmol VL - 133 UR - https://doi.org/10.1001/jamaophthalmol.2015.1128 DO - 10.1001/jamaophthalmol.2015.1128 ID - Mantopoulos2015 ER - TY - JOUR AU - Yeh, O. L. AU - Francis, C. E. PY - 2015 DA - 2015// TI - Ipilimumab-associated bilateral optic neuropathy JO - J Neuroophthalmol VL - 35 ID - Yeh2015 ER - TY - JOUR AU - Kahler, K. C. AU - Hauschild, A. PY - 2011 DA - 2011// TI - Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma JO - J Dtsch Dermatol Ges VL - 9 ID - Kahler2011 ER - TY - JOUR AU - Sanderson, K. AU - Scotland, R. AU - Lee, P. PY - 2005 DA - 2005// TI - Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.128 DO - 10.1200/JCO.2005.01.128 ID - Sanderson2005 ER - TY - JOUR AU - Weber, J. PY - 2007 DA - 2007// TI - Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events JO - Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-7-864 DO - 10.1634/theoncologist.12-7-864 ID - Weber2007 ER -